Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense

Acta Biomaterialia

Volumn 28, Issue , 2015, Pages 171-182

  Sun, Ming ^a   Yang, Chuanxu ^b   Zheng, Jin ^b   Wang, Miao ^a   Chen, Muwan ^b   Le, Dang Quang Svend ^a   Kjems, Jørgen ^b   Bünger, Cody Eric ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Breast cancer stem cells; Co delivery; Doxorubicin; Drug resistance; Non ionic surfactant; siRNA

Indexed keywords

CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DISEASES; GENE EXPRESSION; GENE EXPRESSION REGULATION; NETWORK SECURITY; REPAIR; STEM CELLS; SURFACE ACTIVE AGENTS; TARGETED DRUG DELIVERY;

BREAST CANCER; BREAST CANCER STEM CELL; CANCER STEM CELLS; CO DELIVERIES; DELIVERY SYSTEMS; DOXORUBICIN; DRUG-RESISTANCE; MULTIDRUG RESISTANCE; NON-IONIC SURFACTANTS; SIRNA;

CELL DEATH;

BREAST CANCER RESISTANCE PROTEIN; DOXORUBICIN; LIPOFECTAMINE; NIOSOME; PROTEIN BCL 2; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PHASE CONTRAST MICROSCOPY; PHOTON CORRELATION SPECTROSCOPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME; ZETA POTENTIAL; BREAST TUMOR; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; MULTIDRUG RESISTANCE; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASTIC STEM CELLS;

EID: 84947489548     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2015.09.029     Document Type: Article

References (49)

1. M. Al-Hajj, M.S. Wicha, A. Benito-Hernandez, S.J. Morrison, and M.F. Clarke Prospective identification of tumorigenic breast cancer cells Proc. Natl. Acad. Sci. U.S.A. 100 2003 3983 3988
2. S.K. Singh, and et al. Identification of a cancer stem cell in human brain tumors Cancer Res. 63 2003 5821 5828
3. L.E. Ailles, and I.L. Weissman Cancer stem cells in solid tumors Curr. Opin. Biotechnol. 18 2007 460 466
4. T. Reya, S.J. Morrison, M.F. Clarke, and I.L. Weissman Stem cells, cancer, and cancer stem cells Nature 414 2001 105 111
5. M.E. Ciurea, and et al. Cancer stem cells: biological functions and therapeutically targeting Int. J. Mol. Sci. 15 2014 8169 8185
6. R.I. Pakunlu, T.J. Cook, and T. Minko Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin Pharm. Res. 20 2003 351 359
7. R.I. Pakunlu, Y. Wang, W. Tsao, V. Pozharov, T.J. Cook, and T. Minko Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense novel multicomponent delivery system Cancer Res. 64 2004 6214 6224
8. M. Saad, O.B. Garbuzenko, and T. Minko Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer Nanomedicine (London, England) 3 2008 761 776
9. S.K. Rabindran, D.D. Ross, L.A. Doyle, W. Yang, and L.M. Greenberger Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein Cancer Res. 60 2000 47 50
10. P. Castelo-Branco, and et al. Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition Clin. Cancer Res. 17 2011 111 121
11. T. Hiraga, S. Ito, and H. Nakamura Side population in MDA-MB-231 human breast cancer cells exhibits cancer stem cell-like properties without higher bone-metastatic potential Oncol. Rep. 25 2011 289 296
12. J.M. Adams, and S. Cory The Bcl-2 protein family: arbiters of cell survival Science (New York, NY) 281 1998 1322 1326
13. S.S. Dharap, and et al. Molecular targeting of BCL2 and BCLXL proteins by synthetic BCL2 homology 3 domain peptide enhances the efficacy of chemotherapy J. Pharmacol. Exp. Ther. 316 2006 992 998
14. A. Gross, J.M. McDonnell, and S.J. Korsmeyer BCL-2 family members and the mitochondria in apoptosis Genes Dev. 13 1999 1899 1911
15. S.K. Kassim, and et al. Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer Clin. Biochem. 32 1999 333 338
16. T. Minko, S.S. Dharap, and A.T. Fabbricatore Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic cellular defense Cancer Detect. Prev. 27 2003 193 202
17. J.C. Reed Dysregulation of apoptosis in cancer J. Clin. Oncol. 17 1999 2941 2953
18. Y. Dong, and et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates Proc. Natl. Acad. Sci. U.S.A. 111 2014 3955 3960
19. K.A. Whitehead, and et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity Nat. Commun. 5 2014 4277
20. C. Yang, and et al. Chitosan/siRNA nanoparticles targeting cyclooxygenase type 2 attenuate unilateral ureteral obstruction-induced kidney injury in mice Theranostics 5 2015 110 123
21. M. NVS, and A. Saini Niosomes: a novel drug delivery system Int. J. Res. Pharm. Chem. 1 2011 498 511
22. A. Lohumi A novel drug delivery system: niosomes review J. Drug Deliv. Ther. 2 2012
23. A. Rogerson, J. Cummings, and A.T. Florence Adriamycin-loaded niosomes: drug entrapment, stability and release J. Microencapsul. 4 1987 321 328
24. K. Chandraprakash, N. Udupa, P. Umadevi, and G. Pillai Formulation and evaluation of methotrexate niosomes Ind. J. Pharm. Sci. 55 1993 197
25. K. Suzuki, and K. Sakon The application of liposomes to cosmetics Cosmet. Toilet. 105 1990 65 78
26. C. Zhou, Y. Zhang, B. Yu, M.A. Phelps, L.J. Lee, and R.J. Lee Comparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes Nanomed. Nanotechnol. Biol. Med. 9 2013 504 513
27. C. Zhou, and et al. SPANosomes as delivery vehicles for small interfering RNA (siRNA) Mol. Pharm. 9 2012 201 210
28. A. Valster, N.L. Tran, M. Nakada, M.E. Berens, A.Y. Chan, and M. Symons Cell migration and invasion assays Methods (San Diego, Calif) 37 2005 208 215
29. M. Sun, and et al. A tissue-engineered therapeutic device inhibits tumor growth in vitro and in vivo Acta Biomaterialia 2015
30. S. Jain, S.R. Patil, N.K. Swarnakar, and A.K. Agrawal Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes) Mol. Pharm. 9 2012 2626 2635
31. M.W. Pfaffl, A. Tichopad, C. Prgomet, and T.P. Neuvians Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper-Excel-based tool using pair-wise correlations Biotechnol. Lett. 26 2004 509 515
32. J.H. Rolfing, A. Baatrup, M. Stiehler, J. Jensen, H. Lysdahl, and C. Bunger The osteogenic effect of erythropoietin on human mesenchymal stromal cells is dose-dependent and involves non-hematopoietic receptors and multiple intracellular signaling pathways Stem Cell Rev. 10 2014 69 78
33. T. Minko, S.S. Dharap, R.I. Pakunlu, and Y. Wang Molecular targeting of drug delivery systems to cancer Curr. Drug Targets 5 2004 389 406
34. C.E. Ashley, and et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers Nat. Mater. 10 2011 389 397
35. C.T. Jordan, M.L. Guzman, and M. Noble Cancer stem cells N. Engl. J. Med. 355 2006 1253 1261
36. J.A. Magee, E. Piskounova, and S.J. Morrison Cancer stem cells: impact, heterogeneity, and uncertainty Cancer Cell 21 2012 283 296
37. S.E. Salmon, A.W. Hamburger, B. Soehnlen, B.G. Durie, D.S. Alberts, and T.E. Moon Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs N. Engl. J. Med. 298 1978 1321 1327
38. M. Shipitsin, and et al. Molecular definition of breast tumor heterogeneity Cancer Cell 11 2007 259 273
39. S.C. Steiniger, J.A. Coppinger, J.A. Kruger, J. Yates 3rd, and K.D. Janda Quantitative mass spectrometry identifies drug targets in cancer stem cell-containing side population Stem Cells (Dayton, Ohio) 26 2008 3037 3046
40. S. Zhou, J.J. Morris, Y. Barnes, L. Lan, J.D. Schuetz, and B.P. Sorrentino Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo Proc. Natl. Acad. Sci. U.S.A. 99 2002 12339 12344
41. G. Zhang, Z. Wang, W. Luo, H. Jiao, J. Wu, and C. Jiang Expression of potential cancer stem cell marker ABCG2 is associated with malignant behaviors of hepatocellular carcinoma Gastroenterol. Res. Pract. 2013 2013 782581
42. Z. Madjd, A.Z. Mehrjerdi, A.M. Sharifi, S. Molanaei, S.Z. Shahzadi, and M. Asadi-Lari CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours Cancer Immun. 9 2009 4
43. L.N. Abdullah, and E.K. Chow Mechanisms of chemoresistance in cancer stem cells Clin. Trans. Med. 2 2013 3
44. A. de Fougerolles, H.P. Vornlocher, J. Maraganore, and J. Lieberman Interfering with disease: a progress report on siRNA-based therapeutics Nat. Rev. Drug Discovery 6 2007 443 453
45. Y. Chen, S.R. Bathula, J. Li, and L. Huang Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer J. Biol. Chem. 285 2010 22639 22650
46. Y. Chen, J.J. Wu, and L. Huang Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy Mol. Ther. 18 2010 828 834
47. S.H. Kang, and et al. Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy Pharm. Res. 28 2011 3069 3078
48. J. Panyam, W.Z. Zhou, S. Prabha, S.K. Sahoo, and V. Labhasetwar Rapid endo-lysosomal escape of poly(dl-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery FASEB J. 16 2002 1217 1226
49. J.K. Vasir, and V. Labhasetwar Biodegradable nanoparticles for cytosolic delivery of therapeutics Adv. Drug Deliv. Rev. 59 2007 718 728